The earnings call highlighted a mix of positive developments, such as a favorable litigation settlement and growth in spatial consumables, alongside challenges like declining instrument revenue and a difficult funding environment. While there are areas of growth and strategic advancements, the ongoing challenges in the academic and CapEx environment present significant hurdles.

Company Guidance

During the 10x Genomics Second Quarter 2025 Earnings Conference Call, the company reported a total revenue of $173 million for the quarter, with a notable $68 million recognized upfront from settling worldwide patent litigation with Bruker, which contributed to both operating expenses and license and royalty revenue. Excluding this settlement, revenue was $146 million. The company increased its cash balance by $40 million, not including settlement-related payments. The academic funding landscape remains challenging, with cautious customer spending due to shifting policies and weaker grant disbursements. Despite this, signs of robust underlying demand for single-cell solutions were noted, with Chromium reaction volumes growing year-over-year and sequentially. The company achieved a gross margin of 72%, which included the settlement impact, while operating expenses decreased to $95 million. The acquisition of Scale Biosciences was highlighted as a strategic move to enhance capabilities and broaden access to single-cell analysis. Looking forward, 10x Genomics expects third-quarter revenue to range between $140 million and $144 million, taking into account a $4 million revenue pull-forward in China.

Favorable Patent Litigation Settlement

10x Genomics settled worldwide patent litigation with Bruker on favorable terms, receiving an upfront payment of $68 million, contributing to both operating expenses and license and royalty revenue.

Strong Performance in China

There was a 41% year-over-year increase in APAC revenue, driven by strong performance in China, which benefited from a temporary pull forward in purchasing activity.

Growth in Spatial Consumables Revenue

Spatial consumables revenue increased by 24%, primarily driven by Xenium consumables performance.

Financial Stability and Cash Increase

10x Genomics increased its cash balance by $40 million during the quarter, excluding settlement-related payments.

New Product Launches

Launch of Visium HD 3 Prime and HD cell segmentation capabilities, with upcoming products like Visium HD XL and Xenium RNA plus protein expected to enhance spatial analysis.

10x Genomics (TXG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TXG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.29 / -	-0.3	―	―	―
Aug 07, 2025	2025 (Q2)	-0.37 / 0.28	-0.32	187.50% (+0.60)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.28	-0.5	44.00% (+0.22)	―
Feb 12, 2025	2024 (Q4)	-0.30 / -0.40	-0.41	2.44% (<+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.33 / -0.30	-0.79	62.03% (+0.49)
Aug 08, 2024	2024 (Q2)	-0.48 / -0.32	-0.53	39.62% (+0.21)	―
Apr 30, 2024	2024 (Q1)	-0.50 / -0.50	-0.44	-13.64% (-0.06)	―
Feb 15, 2024	2023 (Q4)	-0.35 / -0.41	-0.15	-173.33% (-0.26)	―
Nov 02, 2023	2023 (Q3)	-0.46 / -0.79	-0.37	-113.51% (-0.42)	―
Aug 03, 2023	2023 (Q2)	-0.40 / -0.53	-0.57	7.02% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TXG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$12.80	$12.29	-3.98%
May 08, 2025	$8.63	$8.77	+1.62%
Feb 12, 2025	$12.00	$11.94	-0.50%
Oct 29, 2024	$15.79	$16.49	+4.43%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does 10X Genomics (TXG) report earnings?

10X Genomics (TXG) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is 10X Genomics (TXG) earnings time?

10X Genomics (TXG) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TXG EPS forecast?

TXG EPS forecast for the fiscal quarter 2025 (Q3) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing